AlphaGen Therapeutics (“AlphaGen”), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative targeted radioligand therapies (RLTs), and ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), jointly announced an exclusive strategic collaboration agreement.
The exclusive agreement enables AlphaGen to use ARTBIO’s AlphaDirect™ isotope isolation technology to generate 212Pb, a unique isotope without a global supply. AlphaGen will also receive rights to develop and commercialize AB001, a clinical-stage alpha RLT targeting prostate-specific membrane antigen (PSMA), in Greater China which includes mainland China, Hong Kong, Macau, and Taiwan. Furthermore, AlphaGen will have the right to use AlphaDirect™ to develop 212Pb RLTs against additional targets. The companies also agreed to an option mechanism for each other’s programs to enable rapid global commercialization.
To read more please visit:
Source: Artbio